Know Cancer

forgot password

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium

Phase 2
18 Years
Open (Enrolling)
Multiple Myeloma

Thank you

Trial Information

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed relapsed multiple
myeloma as defined by the International Myeloma Working Group (IMWG).

- Patients must have measurable disease as defined by the International Uniform
Response Criteria, defined as any of the following:

- serum M-protein of ≥ 500mg/dL

- urine M-protein of ≥ 200mg/ 24 hours

- involved free light chain ≥ 10mg/dL provided serum free light chain ratio is abnormal

- Patients must have had a previous auto-SCT performed as part of a consolidation of an
initial remission and had a remission, defined as a partial response or greater that
lasted at least 12 months either on or off maintenance therapy without evidence of
progression as defined by IMWG criteria.

- Patients who are post auto-SCT as primary therapy must have received maintenance
therapy with lenalidomide.

- Patients must be registered within 6 months of last dose of lenalidomide.

- Minimum of 3 months of maintenance therapy prior to disease progression.

- Age ≥ 18 years.

- Life expectancy of ≥12 weeks.

- KPS ≥ 70 or ECOG < 1 (Appendix IV)

- Patients must have adequate organ and marrow function as defined below:

- ANC ≥ 750/μL

- Platelets≥ 50,000/μL

- Total bilirubin ≤ 1.5 mg/dL

- AST(SGOT) ≤ 3 X upper limit of normal.

- ALT(SGPT) ≤ 3 X upper limit of normal.

- Cardiac Ejection Fraction ≥ 40%

- Serum Creatinine ≤ 2.0 mg/dL

- Patients must have an adequate number of CD34+ stem cells collected to allow for
transplantation (defined as ≥ 2x10^6 CD34+ cells / kg body weight). If not previously
collected and stored or if previous collection was inadequate, the patient must be
willing to undergo stem cell mobilization and collection as per standard practice.

- Patients who participate in this study must be willing and able to tolerate
prophylactic anticoagulation either with aspirin, low-molecular weight heparin
(LMWH), or warfarin.

- Ability to understand and the willingness to sign a written informed consent

- Patient must be determined fit to undergo auto-SCT procedure by a study physician.

- Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days and again
within 24 hours prior to prescribing pomalidomide (prescriptions must be filled
within 7 days) and must either commit to continued abstinence from heterosexual
intercourse or begin TWO acceptable methods of birth control, one highly effective
method and one additional effective method AT THE SAME TIME, at least 28 days before
she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing.
Men must agree to use a latex condom during sexual contact with a FCBP even if they
have had a successful vasectomy. All patients must be counseled at a minimum of every
28 days about pregnancy precautions and risks of fetal exposure.

Exclusion Criteria:

- Patients who have had myeloma therapy within 14 days prior to entering the study or
those who have not recovered from adverse events due to agents administered more than
2 weeks earlier. Patients may have received bisphosphonate therapy or radiation
therapy as part of routine myeloma care at any time prior to study entry.

- Patients may not be receiving any other investigational agents.

- Any prior use of thalidomide or pomalidomide.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to lenalidomide (including thalidomide) or melphalan.

- Known prior positivity for HIV or infectious hepatitis, type B or C.

- Uncontrolled illness including, but not limited to, ongoing or active infection,
symptomatic congestive heart failure , unstable angina pectoris, cardiac arrhythmia,
or psychiatric illness/social situations that would limit compliance with study

- Pregnant and lactating women are excluded from the study because the risks to an
unborn fetus or potential risks in nursing infants are unknown.

- History of thrombosis or thromboembolic event within last 30 days prior to study

- Patients with CNS involvement.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

overall response rate

Outcome Description:

Very Good PR or greater will be evaluated nine months postrandomization according to International Uniform Response Criteria.

Outcome Time Frame:

9 months

Safety Issue:


Principal Investigator

Sergio Giralt, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

December 2012

Completion Date:

December 2015

Related Keywords:

  • Multiple Myeloma
  • CC-4047(Pomalidomide)Pomalyst
  • Stem cell
  • 12-138
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Memorial Sloan Kettering Cancer Center New York, New York  10021
Weill Medical College of Cornell University New York, New York  10021
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey  08903
North Shore LIJ New Hyde Park, New York  11040